Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024
Aytu BioPharma (Nasdaq:AYTU) has scheduled its fiscal 2025 first quarter operational and financial results announcement for November 13, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern time on the same day, including a Q&A session. Interested parties can join via phone using the access code 428941 or watch the webcast live through the company's investor relations website. A replay will be available until November 27, 2024.
Aytu BioPharma (Nasdaq:AYTU) ha programmato l'annuncio dei risultati operativi e finanziari del primo trimestre fiscale 2025 per il 13 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e un webcast alle 16:30, ora dell'Est, lo stesso giorno, inclusa una sessione di domande e risposte. Le parti interessate possono partecipare telefonicamente utilizzando il codice di accesso 428941 o guardare il webcast in diretta attraverso il sito web delle relazioni con gli investitori dell'azienda. Una registrazione sarà disponibile fino al 27 novembre 2024.
Aytu BioPharma (Nasdaq:AYTU) ha programado el anuncio de sus resultados operativos y financieros del primer trimestre fiscal 2025 para el 13 de noviembre de 2024, después del cierre del mercado. La empresa llevará a cabo una llamada de conferencia y un webcast a las 4:30 p.m., hora del Este, el mismo día, incluyendo una sesión de preguntas y respuestas. Las partes interesadas pueden unirse por teléfono utilizando el código de acceso 428941 o ver el webcast en vivo a través del sitio web de relaciones con inversores de la empresa. Una grabación estará disponible hasta el 27 de noviembre de 2024.
Aytu BioPharma (Nasdaq:AYTU)는 2024년 11월 13일 경과 후, 2025 회계연도 1분기 운영 및 재무 실적 발표를 예정하고 있습니다. 회사는 같은 날 동부 표준시 오후 4시 30분에 전화 회의 및 웹캐스트를 진행하며 Q&A 세션이 포함됩니다. 관심 있는 분들은 접속 코드 428941를 사용하여 전화로 참여하거나 회사의 투자자 관계 웹사이트를 통해 웹캐스트를 실시간으로 시청할 수 있습니다. 재생 자료는 2024년 11월 27일까지 이용 가능합니다.
Aytu BioPharma (Nasdaq:AYTU) a prévu l'annonce de ses résultats opérationnels et financiers du premier trimestre de l'exercice 2025 pour le 13 novembre 2024, après la clôture des marchés. L'entreprise animera une conférence téléphonique et un webcast à 16h30, heure de l'Est, le même jour, incluant une session de questions-réponses. Les parties intéressées peuvent rejoindre par téléphone en utilisant le code d'accès 428941 ou regarder le webcast en direct via le site web des relations investisseurs de l'entreprise. Un replay sera disponible jusqu'au 27 novembre 2024.
Aytu BioPharma (Nasdaq:AYTU) hat die Bekanntgabe der Betriebs- und Finanzergebnisse des ersten Quartals des Geschäftsjahres 2025 für den 13. November 2024 nach Börsenschluss anberaumt. Das Unternehmen wird am gleichen Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und ein Webcast veranstalten, einschließlich einer Fragen-und-Antworten-Runde. Interessierte Parteien können per Telefon mit dem Zugangscode 428941 teilnehmen oder den Webcast live über die Investor-Relations-Website des Unternehmens verfolgen. Eine Wiederholung wird bis zum 27. November 2024 verfügbar sein.
- None.
- None.
DENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter of fiscal 2025, after the market close on Wednesday, November 13, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, November 13, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Wednesday, November 13, 2024, at 4:30 p.m. Eastern time
Call-in Information: Interested parties can access the conference call by dialing (877) 545-0320 for United States callers or +1 (973) 528-0002 for international callers and using the participant access code 428941.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster4.com/Webcast/Page/2142/51583, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until November 27, 2024 at (877) 481-4010 for U.S. callers or +1 (919) 882-2331 for international callers and using replay access code 51583.
About Aytu BioPharma, Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Contacts for Investors
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on accesswire.com
FAQ
When will Aytu BioPharma (AYTU) report its Q1 2025 earnings?
How can I access Aytu BioPharma's (AYTU) Q1 2025 earnings call?
Until when will Aytu BioPharma's (AYTU) Q1 2025 earnings call replay be available?
